BPG is committed to discovery and dissemination of knowledge
Featured Articles
2/28/2025 11:47:27 AM | Browse: 115 | Download: 80
 |
Received |
|
2024-10-16 18:56 |
 |
Peer-Review Started |
|
2024-10-18 00:56 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-01-08 06:29 |
 |
Revised |
|
2025-01-08 20:37 |
 |
Second Decision |
|
2025-01-16 02:35 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-01-16 02:54 |
 |
Articles in Press |
|
2025-01-16 02:54 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2025-01-19 17:52 |
 |
Typeset the Manuscript |
|
2025-02-08 01:50 |
 |
Publish the Manuscript Online |
|
2025-02-28 10:45 |
ISSN |
1948-9358 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Endocrinology & Metabolism |
Manuscript Type |
Editorial |
Article Title |
Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach
|
Manuscript Source |
Invited Manuscript |
All Author List |
Vanishri Ganakumar, Cornelius J Fernandez and Joseph M Pappachan |
Funding Agency and Grant Number |
|
Corresponding Author |
Joseph M Pappachan, MD, Professor, Faculty of Science, Manchester Metropolitan University, Lower Ormond Street, Manchester M15 6BH, United Kingdom. drpappachan@yahoo.co.in |
Key Words |
Glucagon-like polypeptide-1 receptor agonists; Cotransporter-2 inhibitors; Cardiovascular disease; Type 2 diabetes mellitus; Cardiovascular outcome trials |
Core Tip |
Glucagon-like polypeptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are important antihyperglycemic medications with cardiovascular (CV) benefits in the form of CV superiority or neutrality, and positive effects on cardiometabolic risk factors. The divergent clinical benefits include significant reductions in hospitalization for heart failure (HF) with SGLT2i, and ischemic stroke and myocardial infarction (MI) with GLP1RA. Zhu et al, in a recent issue of the World Journal of Diabetes, suggest combination therapy with GLP1RA/SGLT2i vs monotherapy with either agent for additional improvement in CV death and recurrent MI, especially in the setting of prior MI or HF. |
Publish Date |
2025-02-28 10:45 |
Citation |
<p>Ganakumar V, Fernandez CJ, Pappachan JM. Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach. <i>World J Diabetes</i> 2025; 16(4): 102390</p> |
URL |
https://www.wjgnet.com/1948-9358/full/v16/i4/102390.htm |
DOI |
https://dx.doi.org/10.4239/wjd.v16.i4.102390 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345